Diagnósticos da América : EBITDA up 11% to BRL 2.5B, leverage down, and operational focus drives margin gains

About this update from Diagnosticos Da America S.a.

EBITDA grew 11% to BRL 2.5 billion in 2024, driven by operational excellence, cost cuts, and business focus. Leverage fell to 4.08x, cash generation surged, and margins improved across both hospital and diagnostics units. JV with Amil and business segregation set the stage for further gains.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Diagnosticos Da America S.a.